Telix Pharmaceuticals Limited (NASDAQ:TLX) signed a strategic agreement on Sunday to merge with ITM Isotope Technologies Munich SE, a major global producer of radioisotopes.
Following the announcement, TLX stock fell nearly 10%.
This acquisition will make the combined organization a vertically integrated industry leader equipped to develop, manufacture, and distribute radiopharmaceutical treatments worldwide.
Financial Terms And Deal Structure
Telix will acquire the private company for a $1.65 billion upfront payment on a cash-free, debt-free basis.
The upfront structure includes $1.25 billion in Telix shares, $302 million in assumed net debt, and $96 million to cover management equity rollovers and transaction expenses.
The sellers can also earn up to $700 million in contingent consideration.
Telix will pay these milestones if the U.S. Food and Drug Administration approves ITM-11 for various indications and the product achieves specific global sales targets by 2030.
Driving Radiopharmaceutical Innovation
Since its founding in 2004, ITM has built a robust commercial manufacturing network spanning more than 65 countries. As a principal supplier of the medical isotope 177Lu, ITM generated $273 million in annual revenue in 2025.
The company’s late-stage pipeline complements Telix’s existing portfolio. ITM’s lead asset, ITM-11, targets neuroendocrine tumors and recently finished one Phase 3 trial while fully enrolling a second.
Regulatory approval for ITM-11 will fast-track Telix’s entry into the commercial therapeutic space.
Investors should note that in August, 177Lu-edotreotide (ITM-11) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) related to the third-party manufacturing.
William Blair noted that Telix management expressed confidence in its ability to navigate future regulatory interactions with the FDA and advance ITM-11 to approval.
Ownership And Revenue Projections
Management estimates the combined organization will generate more than $1.3 billion in unaudited pro forma revenue in 2026.
Continued manufacturing growth, strategic synergies, and cost reductions will likely drive a positive EBITDA contribution starting in 2027.
Telix Pharmaceuticals generated second-quarter revenue of $247 million, up 21% year over year. The company expected fiscal 2026 sales of over $1 billion before the acquisition.
Telix Pharmaceuticals Price Action
TLX Price Action: Telix Pharmaceuticals shares were down 9.85% to $11.35 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
